Expression of granzyme B during primary cytomegalovirus infection after renal transplantation.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Expression of granzyme B during primary cytomegalovirus infection after renal transplantation.

J Infect Dis. 1999 Mar;179(3):693-6. Unique Identifier : AIDSLINE MED/99137808
Wever PC; Spaeny LH; van der Vliet HJ; Rentenaar RJ; Wolbink AM; Surachno J; Wertheim PM; Schellekens PT; Hack CE; ten Berge IJ; Department of Medical Microbiology, Academic Medical Center,; University of Amsterdam, Amsterdam, The Netherlands.

Abstract: CD8+ T cells employ granzyme B (GrB) to induce apoptosis in target cells. Increased expression of GrB has been put forward as a diagnostic marker in transplant rejection and viral infection. Three-color flow cytometric analysis revealed that peripheral blood CD8+ T lymphocytosis during primary cytomegalovirus infection after renal transplantation resulted from expansion of a CD8+GrB+CD62L+ T cell subset that was almost absent during stable transplant function or acute rejection. This expansion coincided with a temporary increase in systemic soluble GrB (sGrB) levels. No such increase was observed during stable transplant function or acute rejection. Thus, the primary immune response to cytomegalovirus infection is accompanied by appearance of CD8+GrB+CD62L+ T cells and increased sGrB levels in the peripheral blood compartment. Determination of the latter may provide a novel approach for monitoring viral infections.

Keywords: JOURNAL ARTICLE Adolescence Adult Child Cytomegalovirus Infections/BLOOD/ENZYMOLOGY/*IMMUNOLOGY CD8-Positive T-Lymphocytes/*ENZYMOLOGY/IMMUNOLOGY Female Flow Cytometry Human *Kidney Transplantation L-Selectin/BLOOD Male Middle Age *Postoperative Complications Prospective Studies Serine Proteinases/BIOSYNTHESIS/*BLOOD Support, Non-U.S. Gov't
990630
A9960909

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .